NASDAQ:ZSAN - Zosano Pharma Stock Price, Forecast & News

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Shares of Zosano Pharma reverse split before market open on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

Zosano Pharma Corp (NASDAQ:ZSAN) issued its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.55) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.03. View Zosano Pharma's Earnings History.

Zosano Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Zosano Pharma.

3 analysts have issued 12 month price targets for Zosano Pharma's stock. Their forecasts range from $6.00 to $16.00. On average, they expect Zosano Pharma's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 604.2% from the stock's current price. View Analyst Price Targets for Zosano Pharma.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zosano Pharma.

News coverage about ZSAN stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Zosano Pharma earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Zosano Pharma.

Some companies that are related to Zosano Pharma include Bellicum Pharmaceuticals (BLCM), Millendo Therapeutics (MLND), Otonomy (OTIC), Axovant Gene Therapies (AXGT), Aquestive Therapeutics (AQST), Sesen Bio (SESN), Scpharmaceuticals (SCPH), AVEO Pharmaceuticals (AVEO), Oramed Pharmaceuticals (ORMP), Immunic (IMUX), Synlogic (SYBX), Proteostasis Therapeutics (PTI), TFF Pharmaceuticals (TFFP), Enlivex Therapeutics (ENLV) and Trevi Therapeutics (TRVI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Iovance Biotherapeutics (IOVA), AEterna Zentaris (AEZS), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Square (SQ), Verastem (VSTM), Protalix Biotherapeutics (PLX), Catalyst Pharmaceuticals (CPRX), Evoke Pharma (EVOK) and TG Therapeutics (TGTX).

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

Zosano Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.55%). Company insiders that own Zosano Pharma stock include Amzak Capital Management, Llc and John Peter Walker. View Institutional Ownership Trends for Zosano Pharma.

ZSAN stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Zosano Pharma.

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ZSAN stock can currently be purchased for approximately $1.42.

Zosano Pharma has a market capitalization of $25.89 million. The biotechnology company earns $-35,360,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.View Additional Information About Zosano Pharma.

The official website for Zosano Pharma is http://www.zosanopharma.com/.

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]